$VRNA
Verona Pharma PLC Stock $vrna

$vrna Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000165731221000018 Filed on August 05, 2021

Income Statement

Concept	2021 Q2	2020 Q4	2020 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.985M	$6.730M	$6.740M
YoY Change	18.47%	1718.92%	22.77%
% of Gross Profit
Research & Development	$20.56M	$8.650M	$7.811M
YoY Change	163.26%	-491.4%	-67.78%
% of Gross Profit
Depreciation & Amortization	$155.0K	$30.00K	$390.0K
YoY Change	-60.26%	-81.25%
% of Gross Profit
Operating Expenses	$28.55M	$15.38M	$10.98M
YoY Change	159.93%	-935.87%	-63.06%
Operating Profit	-$28.55M		-$10.98M
YoY Change	159.93%
Interest Expense	$85.00K	$410.0K	$0.00
YoY Change		-115.07%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$6.505M	$10.00M	$1.960M
YoY Change	231.89%	6.04%	-2550.0%
Pretax Income	-$22.04M	-$4.970M	-$9.023M
YoY Change	144.3%	-158.2%	-66.67%
Income Tax	$25.00K	$7.400M	$15.00K
% Of Pretax Income
Net Earnings	-$22.07M	-$12.36M	-$9.044M
YoY Change	144.01%	921.49%	-58.7%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.05		-$0.08
Diluted Earnings Per Share	-$0.05	-$27.18K	-$0.08
COMMON SHARES
Basic Shares Outstanding	470.8M shares		106.4M shares
Diluted Shares Outstanding	470.8M shares		106.4M shares

Balance Sheet

Concept	2021 Q2	2020 Q4	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$146.0M	$188.0M	$22.40M
YoY Change	551.94%	360.78%	-78.63%
Cash & Equivalents	$146.0M	$188.0M	$22.36M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$2.320M	$1.720M	$5.500M
YoY Change	-57.82%	-14.89%	37.5%
Inventory
Prepaid Expenses	$9.817M	$4.538M
Receivables	$25.00M	$0.00
Other Receivables	$29.11M
Total Short-Term Assets	$216.3M	$202.5M	$31.30M
YoY Change	591.0%	272.95%	-73.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$89.00K	$107.0K	$1.400M
YoY Change	-93.64%	69.84%	133.33%
Goodwill	$545.0K	$545.0K
YoY Change		-6.84%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.219M	$1.702M	$33.50M
YoY Change	-93.38%	-12.09%	509.09%
TOTAL ASSETS
Total Short-Term Assets	$216.3M	$202.5M	$31.30M
Total Long-Term Assets	$2.219M	$1.702M	$33.50M
Total Assets	$218.5M	$204.2M	$64.80M
YoY Change	237.19%	263.14%	-46.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$34.00K	$178.0K	$8.800M
YoY Change	-99.61%	-90.78%	-29.6%
Accrued Expenses	$17.19M	$10.86M
YoY Change		21.09%
Deferred Revenue	$40.05M	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$800.0K
YoY Change			33.33%
Total Short-Term Liabilities	$58.36M	$14.20M	$10.50M
YoY Change	455.85%	10.61%	-38.6%
LONG-TERM LIABILITIES
Long-Term Debt	$4.800M	$4.635M	$0.00
YoY Change
Other Long-Term Liabilities	$974.0K	$500.0K	$30.50M
YoY Change	-96.81%	-28.57%	1594.44%
Total Long-Term Liabilities	$5.741M	$5.149M	$30.50M
YoY Change	-81.18%	689.72%	1594.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$58.36M	$14.20M	$10.50M
Total Long-Term Liabilities	$5.741M	$5.149M	$30.50M
Total Liabilities	$64.11M	$19.35M	$41.00M
YoY Change	56.35%	43.42%	116.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$251.3M	-$207.1M
YoY Change		46.04%
Common Stock	$31.82M	$31.79M
YoY Change		337.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$843.0K	$1.700M
YoY Change
Treasury Stock Shares
Shareholders Equity	$154.4M	$184.9M	$21.85M
YoY Change
Total Liabilities & Shareholders Equity	$218.5M	$204.2M	$64.80M
YoY Change	237.19%	263.14%	-46.71%

Cashflow Statement

Concept	2021 Q2	2020 Q4	2020 Q2
OPERATING ACTIVITIES
Net Income	-$22.07M	-$12.36M	-$9.044M
YoY Change	144.01%	921.49%	-58.7%
Depreciation, Depletion And Amortization	$155.0K	$30.00K	$390.0K
YoY Change	-60.26%	-81.25%
Cash From Operating Activities	-$20.21M	-$12.44M	-$16.01M
YoY Change	26.21%	6.78%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$300.0K	-$140.0K
YoY Change	-100.0%	42.86%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$2.890M	$10.06M
YoY Change	-100.0%	52.91%
Cash From Investing Activities	$0.00	-$2.590M	$9.930M
YoY Change	-100.0%	53.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.399M	-46.21M	-330.0K
YoY Change	930.0%	-12260.53%
NET CHANGE
Cash From Operating Activities	-20.21M	-12.44M	-16.01M
Cash From Investing Activities	0.000	-2.590M	9.930M
Cash From Financing Activities	-3.399M	-46.21M	-330.0K
Net Change In Cash	-23.61M	-61.24M	-6.410M
YoY Change	268.25%	372.53%
FREE CASH FLOW
Cash From Operating Activities	-$20.21M	-$12.44M	-$16.01M
Capital Expenditures	$0.00	$300.0K	-$140.0K
Free Cash Flow	-$20.21M	-$12.74M	-$15.87M
YoY Change	27.32%	7.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001657312
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38067
	dei	Entity Registrant Name EntityRegistrantName	Verona Pharma plc
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1489389
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 More London Riverside
	dei	Entity Address City Or Town EntityAddressCityOrTown	London
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	SE1 2RE
	dei	Entity Address Country EntityAddressCountry	GB
	dei	Country Region CountryRegion	44
	dei	City Area Code CityAreaCode	203
	dei	Local Phone Number LocalPhoneNumber	283 4200
	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.05 per share*
	dei	Trading Symbol TradingSymbol	VRNA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	480291822	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	146035000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187986000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25002000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9817000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4538000	USD
CY2021Q2	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	14108000	USD
CY2020Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	8260000	USD
CY2021Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	4001000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0	USD
CY2021Q2	vrna	Equity Interest Receivable EquityInterestReceivable	15000000	USD
CY2020Q4	vrna	Equity Interest Receivable EquityInterestReceivable	0	USD
CY2021Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2320000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1720000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	216283000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	202504000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1050000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	89000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	107000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	545000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	545000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1585000	USD
CY2021Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	2219000	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1702000	USD
CY2021Q2	us-gaap	Assets Assets	218502000	USD
CY2020Q4	us-gaap	Assets Assets	204206000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	34000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	178000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17188000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10863000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	40051000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	749000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	798000	USD
CY2021Q2	vrna	Warrant Liability Current WarrantLiabilityCurrent	42000	USD
CY2020Q4	vrna	Warrant Liability Current WarrantLiabilityCurrent	2246000	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	300000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	118000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	58364000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14203000	USD
CY2021Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4767000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4635000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	974000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	514000	USD
CY2021Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5741000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5149000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	64105000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	19352000	USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	488739150	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	488304446	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	471839302	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	463304446	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	31824000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	31794000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	379282000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	366411000	USD
CY2021Q2	us-gaap	Treasury Stock Value TreasuryStockValue	843000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1700000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-251265000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-207050000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	154397000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	184854000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	218502000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	204206000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20563000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7811000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34137000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15433000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7985000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3172000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17267000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10034000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	28548000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	10983000	USD
	us-gaap	Operating Expenses OperatingExpenses	51404000	USD
	us-gaap	Operating Expenses OperatingExpenses	25467000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-28548000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10983000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-51404000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25467000	USD
CY2021Q2	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	3836000	USD
CY2020Q2	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	1786000	USD
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	5906000	USD
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	3471000	USD
CY2021Q2	us-gaap	Investment Income Net InvestmentIncomeNet	3000	USD
CY2020Q2	us-gaap	Investment Income Net InvestmentIncomeNet	34000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	7000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	103000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	85000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	169000	USD
CY2021Q2	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	40000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2021Q2	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	2711000	USD
CY2020Q2	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	89000	USD
	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	2204000	USD
	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	231000	USD
CY2020Q2	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	51000	USD
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	203000	USD
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	344000	USD
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6505000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1960000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8151000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4149000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22043000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9023000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43253000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21318000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	105000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-22068000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-9038000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-43358000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21384000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-164000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2321000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22068000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9202000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43358000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23705000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	470786767	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	470786767	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106360580	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106360580	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	469036978	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	469036978	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105908648	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105908648	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	184854000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-21290000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	172414000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8850000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-22068000	USD
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3782000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7450000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	383000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	154397000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	42741000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12346000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2157000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	52000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1867000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	30157000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-9038000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-164000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-43358000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21384000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-52000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	950000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	21853000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	186000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	214000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	70000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	63000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2204000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-231000	USD
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	289000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	16300000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2817000	USD
	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	305000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	315000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	25002000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	vrna	Increase Decrease In Equity Interest Receivable IncreaseDecreaseInEquityInterestReceivable	15000000	USD
	vrna	Increase Decrease In Equity Interest Receivable IncreaseDecreaseInEquityInterestReceivable	0	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5279000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2873000	USD
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	5848000	USD
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	-5894000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	600000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-713000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4823000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	716000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-144000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-953000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6325000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-561000	USD
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	393000	USD
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	406000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	40051000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	182000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	213000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38756000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16285000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	USD
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	0	USD
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	9792000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9787000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3782000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	383000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3399000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	204000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1570000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-41951000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8068000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187986000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30428000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146035000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22360000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	109000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	subsidiary
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	subsidiary
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-251300000	USD
CY2021Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	434704	shares
CY2021Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.90
CY2021Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	400000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, estimation of contract consideration and revenue recognition, the fair value of share-based compensation and the fair value of warrants. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Critically, management are required to identify the promises in the contract, determine whether these promises are distinct and determine when the Company has satisfied these obligations. The Company’s consideration of these issues is discussed in Note 8.</span></div>
CY2020Q4	vrna	Prepaid Research And Development Fees Current PrepaidResearchAndDevelopmentFeesCurrent	2551000	USD
CY2021Q2	us-gaap	Prepaid Insurance PrepaidInsurance	3864000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1701000	USD
CY2021Q2	vrna	Prepaid Research And Development Fees Current PrepaidResearchAndDevelopmentFeesCurrent	5643000	USD
CY2021Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	310000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	286000	USD
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9817000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4538000	USD
CY2021Q2	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	14108000	USD
CY2020Q4	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	8202000	USD
CY2021Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	58000	USD
CY2021Q2	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	14108000	USD
CY2020Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	8260000	USD
CY2021Q2	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	11227000	USD
CY2020Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	8607000	USD
CY2021Q2	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	4925000	USD
CY2020Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	2149000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1036000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	107000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	34504825	shares
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17188000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10863000	USD
	vrna	Class Of Warrant Or Right Number Of Exercised Or Forfeited ClassOfWarrantOrRightNumberOfExercisedOrForfeited	0	shares
CY2021Q1	vrna	Class Of Warrant Or Right Number Of Exercised Or Forfeited ClassOfWarrantOrRightNumberOfExercisedOrForfeited	0	shares
CY2021Q2	vrna	Class Of Warrant Or Right Intrinsic Value ClassOfWarrantOrRightIntrinsicValue	0	USD
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12401262	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12401262	shares
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2021Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y10M2D
CY2020Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P1Y3M29D
CY2021Q2	vrna	Warrant Liability Current WarrantLiabilityCurrent	42000	USD
CY2020Q4	vrna	Warrant Liability Current WarrantLiabilityCurrent	2246000	USD
CY2021Q2	vrna	Sensitivity Analysis Of Fair Value Warrant Liability Impact Of10 Percent Increase In Volatility Rate SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate	125000	USD
CY2021Q2	vrna	Warrant Liability Fair Value WarrantLiabilityFairValue	42000	USD
CY2021Q2	vrna	Sensitivity Analysis Of Fair Value Warrant Liability Impact Of10 Percent Decrease In Volatility Rate SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate	8000	USD
CY2021Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4800000	USD
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7451000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	950000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16300000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2817000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13125672	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.41
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	996720	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.17
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12128952	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.43
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	800000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.73
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12928952	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.38
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21384000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21384000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-22068000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-9038000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-43358000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21384000	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-22068000	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22068000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9038000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9038000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-43358000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	470786767	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	470786767	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106360580	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106360580	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	469036978	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	469036978	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105908648	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105908648	shares
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	75713291	shares

Files In Submission

Name	View Source	Status
0001657312-21-000018-index-headers.html	Edgar Link	pending
0001657312-21-000018-index.html	Edgar Link	pending
0001657312-21-000018.txt	Edgar Link	pending
0001657312-21-000018-xbrl.zip	Edgar Link	pending
exhibit101q221.htm	Edgar Link	pending
exhibit311q221.htm	Edgar Link	pending
exhibit312q221.htm	Edgar Link	pending
exhibit321q221.htm	Edgar Link	pending
exhibit322q221.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrna-20210630.htm	Edgar Link	pending
vrna-20210630.xsd	Edgar Link	pending
vrna-20210630_cal.xml	Edgar Link	unprocessable
vrna-20210630_def.xml	Edgar Link	unprocessable
vrna-20210630_htm.xml	Edgar Link	completed
vrna-20210630_lab.xml	Edgar Link	unprocessable
vrna-20210630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRNA
Verona Pharma PLC Stock $vrna

2021 Q2 Form 10-Q Financial Statement

#000165731221000018 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA Verona Pharma PLC Stock $vrna

2021 Q2 Form 10-Q Financial Statement

#000165731221000018 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA
Verona Pharma PLC Stock $vrna